Drugs / HF10
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01017185 | Aug 2009 → May 2014 | breast carcinoma, head and neck cancer, melanoma, skin squamous cell carcinoma | Takara Bio Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03259425 | Jan → Sep 2018 | melanoma | University of Utah | Terminated | No outcome recorded |
| Phase 2 | NCT02272855 | Apr 2014 → Oct 2016 | melanoma | Takara Bio Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HF10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02272855 ↗ |
| Modality | Other / unclassified | “the oncolytic virus, HF10” NCT01017185 ↗ |
| Route | Other | “intratumoral injections of HF10” NCT02272855 ↗ |